Different points on the research spectrum were under the microscope at the Wharton Health Care Business Conference last month as two panels of biotech pharmaceutical and investment leaders discussed the state of R&D among big pharmaceuticals and the progress of stem cell research. While disappointing results in both sectors have dominated the news lately panelists at each session also noted some promising developments -- and causes for optimism -- in their respective fields.
Hosted on Acast. See acast.com/privacy for more information.
Knowledge at Wharton